Business Wire

CA-ERGOMOTION

29.10.2020 22:30:09 CET | Business Wire | Press release

Share
Ergomotion Announces Opening of First Manufacturing Facility in North America

Ergomotion , part of the Keeson Technology Group and the largest manufacturer of adjustable bases worldwide, will open a 250,000 square foot manufacturing facility in Ciudad Juárez, Chihuahua, the company’s first assembly plant in North America. The expansion was fueled by the decision to increase product capabilities, oversee manufacturing functions, and ultimately to stay closer to Ergomotion’s customer base in the United States.

“We see a prime opportunity with the North America expansion to enhance the customer service experience in the U.S.,” says Johnny Griggs, Chief Operating Officer at Ergomotion. “Our goal is to provide our partners with world class manufacturing and supply chain and to help grow and strengthen their business. We’re excited to partner with Ciudad Juárez to expand our manufacturing capabilities and make this project viable and successful.”

Ergomotion is making a significant investment that will allow for the creation of 400 jobs, within the local economy. The Juárez facility is located in the high growth southeast quadrant of the city and is approximately 8.5 miles from the U.S. border. The project expects to direct capital investment of $4.5 million USD. Ergomotion’s long-term goal is to strengthen their operations and continue to open new facilities in the United States to better serve existing customers, retailers and strategic partners.

“Ciudad Juárez is thrilled to see Ergomotion grow their North American footprint here, in our hometown,” says Hector Armando Cabada Alvidrez, Mayor of Ciudad Juárez. “We are looking forward to working together to strengthen our local economy and seeing the opportunities that the expansion will create for our community.”

“Our state is proven to be one of the most competitive in the world for manufacturing. We are confident that no effort will be spared to continue making our region the most innovative, efficient and fast growing in North America. We know Ergomotion will be pleased with the workforce in Ciudad Juárez and hope this will be their new home for many decades to come,” says Alejandra de la Vega, Secretary of Innovation and Economic Development of the State of Chihuahua.

The new manufacturing facility will accommodate the constant growth surge that the adjustable base category has experienced over the past 10 years and during the pandemic. The facility will include manual and semi-automatic operations that will support continued enhancement of customer service within the U.S., ensuring a reliable and high-quality supply chain for Ergomotion products.

ABOUT ERGOMOTION

Ergomotion, headquartered in Santa Barbara, California, is the largest manufacturer of adjustable bases worldwide. The company’s products are created to provide a holistic wellness solution infused with smart technology to enrich sleep, health, and the overall quality of life. Ergomotion’s adjustable bases are designed to accommodate the industry’s leading mattresses and to seamlessly integrate with existing bed frames. The products have been sold in more than 30 countries to over 170 major brands. Ergomotion is part of the Keeson Technology Group family based in Jiaxing City, China. To learn more about Ergomotion visit www.ergomotion.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye